Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) EBITDA (2017 - 2025)

Historic EBITDA for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to -$129.5 million.

  • Crinetics Pharmaceuticals' EBITDA fell 7361.66% to -$129.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$422.9 million, marking a year-over-year decrease of 5379.28%. This contributed to the annual value of -$298.4 million for FY2024, which is 4236.26% down from last year.
  • Per Crinetics Pharmaceuticals' latest filing, its EBITDA stood at -$129.5 million for Q3 2025, which was down 7361.66% from -$116.0 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' 5-year EBITDA high stood at -$22.9 million for Q1 2021, and its period low was -$129.5 million during Q3 2025.
  • Moreover, its 5-year median value for EBITDA was -$53.4 million (2023), whereas its average is -$61.0 million.
  • In the last 5 years, Crinetics Pharmaceuticals' EBITDA plummeted by 1453.81% in 2023 and then crashed by 7361.66% in 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' EBITDA (Quarter) stood at -$31.2 million in 2021, then plummeted by 40.91% to -$43.9 million in 2022, then tumbled by 32.66% to -$58.3 million in 2023, then plummeted by 40.19% to -$81.7 million in 2024, then tumbled by 58.59% to -$129.5 million in 2025.
  • Its last three reported values are -$129.5 million in Q3 2025, -$116.0 million for Q2 2025, and -$95.7 million during Q1 2025.